n-methyl-3,4-methylenedioxyamphetamine has been researched along with Disease Exacerbation in 7 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, X | 1 |
| Li, S | 1 |
| Li, J | 1 |
| Qi, R | 1 |
| Zhong, L | 1 |
| Yu, H | 1 |
| Costa, G | 1 |
| Spulber, S | 1 |
| Paci, E | 1 |
| Casu, MA | 1 |
| Ceccatelli, S | 1 |
| Simola, N | 1 |
| Morelli, M | 1 |
| O'Donnell, A | 1 |
| Addison, M | 1 |
| Spencer, L | 1 |
| Zurhold, H | 1 |
| Rosenkranz, M | 1 |
| McGovern, R | 1 |
| Gilvarry, E | 1 |
| Martens, MS | 1 |
| Verthein, U | 1 |
| Kaner, E | 1 |
| Breivik, T | 1 |
| Bogen, IL | 1 |
| Haug, KH | 1 |
| Fonnum, F | 1 |
| Opstad, PK | 1 |
| Eide, DM | 1 |
| Myhre, O | 1 |
| O'Suilleabhain, P | 1 |
| Giller, C | 1 |
| Swan, MC | 1 |
| Lam, D | 1 |
| Giele, HP | 1 |
| Reid, LW | 1 |
| Elifson, KW | 1 |
| Sterk, CE | 1 |
1 review available for n-methyl-3,4-methylenedioxyamphetamine and Disease Exacerbation
| Article | Year |
|---|---|
Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature.
Topics: Amphetamine-Related Disorders; Disease Progression; Humans; Methamphetamine; Motivation; N-Methyl-3, | 2019 |
6 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Disease Exacerbation
| Article | Year |
|---|---|
MDMA targets miR-124/MEKK3 via MALAT1 to promote Parkinson's disease progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Disease Progression; Dopaminergic Neurons; Humans; MicroRNAs; | 2023 |
In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice.
Topics: Age Factors; Animals; Brain; Calcium-Binding Proteins; Dexamethasone; Disease Models, Animal; Diseas | 2021 |
Effects of long-term exposure of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on neuronal transmitter transport, brain immuno-regulatory systems and progression of experimental periodontitis in rats.
Topics: Alveolar Bone Loss; Animals; Brain; Brain Chemistry; Disease Progression; Male; N-Methyl-3,4-methyle | 2014 |
Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs.
Topics: Adult; Antiparkinson Agents; Disease Progression; Hallucinogens; Hepatitis C; Humans; Indoles; Male; | 2003 |
Intravascular ecstasy: an unusual cause of thigh compartment syndrome.
Topics: Amphetamine-Related Disorders; Compartment Syndromes; Debridement; Disease Progression; Extracellula | 2006 |
Ecstasy and gateway drugs: initiating the use of ecstasy and other drugs.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Behavior, Addictive; Cocaine-Related Disorders; Cr | 2007 |